Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now

Stocks The Globe and Mail By The Globe and Mail 05 Oct 2026 20:08 1 min read
Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now

Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now  The Globe and Mail

Covered in this story

Analyst targets on Pfizer

Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.

Call it yourself

No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.

Make the first call on Pfizer →

Dalsna Finance is currently tracking 48 stories mentioning Pfizer, the earliest published 25 May 2026.

Read the full story on The Globe and Mail → Opens the original article on news.google.com

Summary aggregated from The Globe and Mail's public RSS feed. The full reporting belongs to The Globe and Mail — please read it on their site.